Collectively, these findings demonstrat that IGF2BP2 is highly expressed in pancreatic cancer, is an independent predictor of prognosis and performs well in predicting the outcomes of patients with pancreatic cancer. Here, IGF2BP2 is linked to familial pancreatic carcinoma.